Q3 EPS Estimate for Mirum Pharmaceuticals Raised by Analyst

Key Points

• HC Wainwright raised Mirum Pharmaceuticals’ Q3 2026 EPS estimate to a loss of $0.31 per share from a prior estimate of $1.06, while maintaining a “Buy” rating and $140 price target.
• Mirum’s latest quarter showed mixed results: EPS of negative $1.06 missed the $0.74 consensus estimate, but revenue of $176.24 million exceeded expectations and increased 37.9% year over year.
• Analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $137.33, although an unexpected FDA request for a Phase 3 study could create near-term regulatory and spending pressures.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a note issued to investors on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($1.06). HC Wainwright has a "Buy" rating and a $140.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($4.42) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.40 EPS, Q4 2027 earnings at $0.64 EPS, FY2027 earnings at $1.28 EPS, FY2028 earnings at $3.96 EPS, FY2029 earnings at $5.71 EPS and FY2030 earnings at $7.12 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company had revenue of $176.24 million during the quarter, compared to analysts' expectations of $166.33 million. During the same quarter in the previous year, the company earned ($0.12) EPS. The business's quarterly revenue was up 37.9% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on the stock. Morgan Stanley set a $137.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday. Wall Street Zen raised shares of Mirum Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Wolfe Research began coverage on Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $137.33.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM opened at $100.65 on Monday. The stock has a 50 day moving average of $110.33 and a 200 day moving average of $101.86. The company has a market cap of $6.54 billion, a PE ratio of -6.92 and a beta of 0.52. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a 12-month low of $57.79 and a 12-month high of $130.00.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 2,721 shares of the firm's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares in the company, valued at $373,680. This trade represents a 46.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,155 shares of company stock valued at $7,185,662 in the last 90 days. Insiders own 8.32% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth about $513,945,000. Janus Henderson Group PLC lifted its holdings in shares of Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company's stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. State Street Corp lifted its holdings in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company's stock valued at $169,354,000 after acquiring an additional 797,088 shares during the last quarter. Wellington Management Group LLP grew its position in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock worth $57,965,000 after acquiring an additional 672,118 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Mirum Pharmaceuticals in the second quarter worth about $78,434,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source